Vir Biotechnology Inc
VIR5.095USD
+0.065+1.29%
交易中 （美东）报价延迟15分钟
703.43M总市值
亏损市盈率 TTM
关于 Vir Biotechnology Inc 公司
Vir Biotechnology, Inc. 是一家免疫学公司，专注于结合尖端技术来治疗和预防严重传染病和其他严重疾病。该公司的临床开发产品线包括针对丁型肝炎病毒 (HDV)、乙型肝炎病毒 (HBV) 和人类免疫缺陷病毒 (HIV) 的产品候选药物。该公司的产品线中还有几种临床前候选药物，包括针对甲型和乙型流感、COVID-19、呼吸道合胞病毒和人类亚肺病毒 (RSV 和 MPV) 以及人乳头瘤病毒 (HPV) 的产品。该公司的产品线包括 VIR-1949、VIR-7229、VIR-2981、VIR-8190 和 HIV Cure。该公司还致力于开发 tobevibart（一种也称为 VIR-3434 的单克隆抗体）和 Elebsiran（一种也称为 VIR-2218 的 siRNA），用于治疗和抑制慢性 HDV。该公司的 Elebsiran 是一种正在研究的针对 HBV 的 siRNA，可以降低 HBsAg（一种 HDV 病毒生命周期所需的蛋白质）。
公司简介
公司代码VIR
公司名称Vir Biotechnology Inc
上市日期Oct 11, 2019
CEODr. Marianne De Backer, Ph.D.
员工数量408
证券类型Ordinary Share
年结日Oct 11
公司地址1800 Owens Street
城市SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94158
电话14159064324
网址https://www.vir.bio/
公司代码VIR
上市日期Oct 11, 2019
CEODr. Marianne De Backer, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
32.66K
-30.05%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Director
Independent Director
23.81K
+50.61%
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
19.03K
-80.53%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
14.62K
+120.86%
Dr. Norbert W. Bischofberger, Ph.D.
Dr. Norbert W. Bischofberger, Ph.D.
Independent Director
Independent Director
8.00K
--
Ms. Vanina De Verneuil, J.D.
Ms. Vanina De Verneuil, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
4.69K
-94.10%
Dr. Mark Eisner, M.D.
Dr. Mark Eisner, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Ms. Janet Napolitano, J.D.
Ms. Janet Napolitano, J.D.
Independent Director
Independent Director
--
--
Mr. Jason V. O'byrne
Mr. Jason V. O'byrne
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Vicki L. Sato, Ph.D.
Dr. Vicki L. Sato, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
32.66K
-30.05%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Director
Independent Director
23.81K
+50.61%
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
19.03K
-80.53%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
14.62K
+120.86%
Dr. Norbert W. Bischofberger, Ph.D.
Dr. Norbert W. Bischofberger, Ph.D.
Independent Director
Independent Director
8.00K
--
Ms. Vanina De Verneuil, J.D.
Ms. Vanina De Verneuil, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
4.69K
-94.10%
收入明细
FY2024
暂无数据
地区USD
名称
营收
占比
United States
74.20M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 6月5日 周四
更新时间: 6月5日 周四
持股股东
股东类型
持股股东
持股股东
占比
SB Investment Advisers (UK) Limited
12.07%
BlackRock Institutional Trust Company, N.A.
10.40%
ARCH Venture Partners
9.34%
The Vanguard Group, Inc.
9.25%
GSK plc
6.19%
Other
52.75%
持股股东
持股股东
占比
SB Investment Advisers (UK) Limited
12.07%
BlackRock Institutional Trust Company, N.A.
10.40%
ARCH Venture Partners
9.34%
The Vanguard Group, Inc.
9.25%
GSK plc
6.19%
Other
52.75%
股东类型
持股股东
占比
Investment Advisor
28.96%
Investment Advisor/Hedge Fund
15.19%
Private Equity
13.70%
Venture Capital
10.23%
Hedge Fund
7.60%
Corporation
6.19%
Individual Investor
4.39%
Research Firm
1.90%
Foundation
1.13%
Other
10.73%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
530
124.95M
90.39%
-15.17M
2025Q1
571
125.80M
91.30%
-16.44M
2024Q4
568
122.14M
89.06%
-13.83M
2024Q3
554
118.76M
86.83%
-17.44M
2024Q2
572
119.53M
87.47%
-20.55M
2024Q1
564
122.68M
91.07%
-16.10M
2023Q4
577
121.87M
90.75%
-16.40M
2023Q3
578
123.93M
92.29%
-3.81M
2023Q2
574
125.10M
93.31%
+332.42K
2023Q1
568
121.09M
90.65%
+1.82M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
SB Investment Advisers (UK) Limited
16.68M
12.07%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
14.37M
10.4%
-298.87K
-2.04%
Mar 31, 2025
ARCH Venture Partners
12.92M
9.34%
--
--
Apr 01, 2025
The Vanguard Group, Inc.
12.78M
9.25%
-323.13K
-2.47%
Mar 31, 2025
GSK plc
8.55M
6.19%
--
--
Apr 01, 2025
State Street Global Advisors (US)
5.73M
4.14%
+652.43K
+12.86%
Mar 31, 2025
Scangos (George A)
3.78M
2.73%
-550.77K
-12.72%
Apr 01, 2025
Dimensional Fund Advisors, L.P.
2.68M
1.94%
+768.95K
+40.14%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.30M
1.66%
+98.43K
+4.48%
Mar 31, 2025
OrbiMed Advisors, LLC
2.25M
1.63%
-970.37K
-30.15%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Genomics Immunology and Healthcare ETF
1.03%
Virtus LifeSci Biotech Clinical Trials ETF
0.87%
Global X Genomics & Biotechnology ETF
0.57%
ALPS Medical Breakthroughs ETF
0.47%
Invesco NASDAQ Future Gen 200 ETF
0.46%
Invesco S&P SmallCap Health Care ETF
0.33%
Hypatia Women CEO ETF
0.18%
SPDR S&P Biotech ETF
0.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.1%
WisdomTree US SmallCap Quality Growth Fund
0.09%
查看更多
iShares Genomics Immunology and Healthcare ETF
占比1.03%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.87%
Global X Genomics & Biotechnology ETF
占比0.57%
ALPS Medical Breakthroughs ETF
占比0.47%
Invesco NASDAQ Future Gen 200 ETF
占比0.46%
Invesco S&P SmallCap Health Care ETF
占比0.33%
Hypatia Women CEO ETF
占比0.18%
SPDR S&P Biotech ETF
占比0.17%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.1%
WisdomTree US SmallCap Quality Growth Fund
占比0.09%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
